Amer Zeidan, MBBS, MHS is an Associate Professor of Medicine (Hematology) at Yale University. He is also the medical director of Hematology Early Therapeutics Research, the leader of the Myeloid malignancies DART (Disease Aligned Research Team), and the director of CME at Hematology division at Yale Cancer Center. Dr. Zeidan has completed a hematology/oncology fellowship and a clinical research fellowship in myelodysplastic syndromes (MDS) at Johns Hopkins University where he also earned a Master of Health Science (MHS) degree in Clinical Investigation. Dr. Zeidan specializes in the management of myeloid malignancies especially MDS and acute myeloid leukemia (AML). The focus of Dr. Zeidan’s clinical/translational research is the development of novel therapies for myeloid malignancies, with a special focus on targeted therapies and immunotherapy-based approaches. Dr. Zeidan is also active in health outcomes and comparative effectiveness research for blood cancers diseases and their therapies.
Valeria Santini is Associate Professor of Hematology at the University of Florence, Italy. She runs the MDS Unit- Hematology- Department of Experimental and Clinical Medicine- AOU Careggi, University of Florence. Her interests are focused on clinical and translational research in MDS and elderly AML. Professor Santini is President of the Scientific Committee of Fondazione Italiana per lo studio delle sindromi mielodisplastiche (FISiM) and Italian Network of MDS Registries. She belongs to ASH, EHA SOHO and MDS Foundation. She is also an author of more than 200 peer-reviewed papers published in international journals, she has been member of the Editorial board of Blood journal, and documented reviewer for high impact factor scientific journals. She has been an invited speaker at numerous international meetings including the American Society of Clinical Oncology (ASCO 2007: educational session on MDS), American Society of Hematology (ASH 2012, ASH 2016: educational sessions on MDS), European Haematology Association (EHA 2016, EHA 2020, EHA 2022: Educational sessions on MDS) and national haematology societies of several countries.
Dr. Hamadani, is a Professor of Medicine and Director of the BMT & Cellular Therapy Program at the Medical College of Wisconsin, USA. His clinical and research focus is lymphoma, transplant and cellular therapy. He is the Scientific Director of Lymphoma Observation Research Program of CIBMTR, and the Co-Chair of the ASTCT Committee on Practice Guidelines. He has been lead investigator of a number of drug development trials and has authored over 350 peer reviewed manuscripts.
Mohamed A. Kharfan-Dabaja, MD, MBA, FACP Professor of Medicine
Director, Blood and Marrow Transplantation and Cellular Therapies
Medical Director, Cancer Research Office (Florida Campus)
Director, Inpatient Hematology Unit
Mayo Clinic Florida
Dr. Kharfan-Dabaja is a Professor of Medicine, Vice-Chair of Hematology, and the Director of the Blood and Marrow Transplantation and Cellular Immune Therapies programs at Mayo Clinic in Jacksonville, FL. His main interests are chimeric antigen receptor T-cell (CAR-T) therapy for lymphoid neoplasms and reduced intensity allogeneic hematopoietic cell transplantation for various hematologic malignancies.
He is Board certified in Medical Oncology and Hematology. He is a co-Chair of the Lymphoma Working Committee of the Center for International Blood and Marrow Transplant Research (CIBMTR), the chair of the Payer Relation Committee and a member of the Clinical Practice Guidelines Committee of the American Society for Transplantation and Cellular Therapy, and a member of the Committee on Investment and Audit of the American Society of Hematology.
He has published over 330 peer-reviewed manuscripts, 21 book chapters and has presented his work at various regional, national and international scientific platforms.
After completing my Internal Medicine training at Johns Hopkins, in the Osler Medical Program, I subsequently completed both hematology and oncology training at MD Anderson Cancer Center (MDACC). I was selected as a chief fellow in my second year of training. I obtained ABIM board certification in Internal Medicine, Hematology and Oncology, and continued my career at MDACC as an Assistant Professor in the Department of Leukemia. I have an active clinical schedule during which I see patients: 2 full days of clinic per week, and 2 months of inpatient service per year. I have fellow teaching responsibilities as a Leukemia hematology/oncology Course Director and was the sole recipient of the MDACC Gerald P Bodey Award for Excellence in Education in 2020. My clinical/translational research work has been focused on improving outcomes and developing novel therapies for patients with rare myeloid malignancies, including for adolescents, young adults, and older adult patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Myeloproliferative Neoplasms (MPN) and Acute Myeloid Leukemia (AML).
Professor Claire Harrison graduated from Oxford Univeristy Medical School and became a consultant at the Guy’s and St Thomas Hospital in 2001, where she is now a deputy medical director.
The focus of her clinical work is myeloproliferative neoplasms (MPN), for which she has a national and international reputation. Key areas of interest are clinical trials and associated translational research. In addition to the PT-1 trial, MAJIC, COMFORT-II, JAKARTA-2 and PERSIST-1 where she is currently the global chief or co-chief investigator, she has a leadership role in over 20 clinical trials. This work has led to the approval of new therapies such a ruxolitinib, fedratinib and pacritinib. Translational research has been supported with a grant income of over £10M in the past 5 years. JAK2 exon 12 mutations, genetic suseptibility and the impact of the order of mutations in MPN. In the past 10 years she has published widely (>250 academic articles).
In addition she has a strong interest in patient advocacy and founded the UK MPN group www.mpnvoice.org.uk.
The clinical MPN service at GSTT is large, comprehensive and is internationally recognised as a centre of excellence.
Dr. Mesa serves as the executive director of the Mays Cancer Center, one of only four National Cancer Institute-designated Cancer Centers in Texas. Dr. Mesa is internationally renowned expert on myeloproliferative neoplasms (MPNs), a group of bone marrow disorders that often lead to leukemia. He has been the principal investigator or co-principal investigator of more than 100 clinical trials and co-led the research teams leading to the FDA’s approval of 4 drugs including ruxolitinib, fedratinib, ropegylated interferon, and pacritinib. Dr. Mesa earned his Bachelor of Science degrees in nuclear engineering and physiology, with minors in radiation biophysics and bioengineering, from the University of Illinois at Urbana-Champaign. He received his medical degree, completed his residency in internal medicine and fulfilled his fellowship in hematology/medical oncology from the Mayo Graduate School at the Mayo Clinic College of Medicine in Rochester, Minnesota. He is a fellow of the American College of Physicians and is certified by the American Board of Internal Medicine in internal medicine and medical oncology. Dr. Mesa has been elected to the boards of the American Association of Cancer Institutes and is an officer of the board of the Leukemia and Lymphoma Society.
This site place cookies on your machine for reasons including keeping track of your preferences, collecting aggregated statistics to analyze how our site is used, and to show you ads tailored to your interests. ACCEPT
Privacy, Cookies Policy, General Terms and Conditions of Use
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.